Physician profile
Michael D Lee
NPI 1013114933
$2,986.38
in general payments reported to CMS, 2019-2025
30 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $162 · 2021: $614 · 2022: $73.24 · 2023: $504 · 2024: $383 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $495.31 | 2020-2025 | Airsupra, Tezspire |
| Abbvie INC. | $305.16 | 2019-2025 | |
| Lilly USA, LLC | $292.84 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $214.61 | 2019-2024 | |
| Genzyme Corporation | $188.57 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $187.86 | 2019-2023 | Vaxneuvance, Rotateq, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $162.04 | 2019 | |
| Glaxosmithkline, LLC. | $148.61 | 2022-2023 | Nucala, Shingrix |
| Galderma Laboratories, L.P. | $97.96 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $97.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.30 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $78.87 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $70.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $60.14 | 2019-2025 | Freestyle Libre 3 |
| Valeritas, INC. | $59.11 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $52.70 | 2023 | Inspire |
| Regeneron Healthcare Solutions, INC. | $49.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.51 | 2019 | |
| Dermira, INC. | $36.82 | 2019 | |
| Shire North American Group INC | $35.96 | 2019 | |
| Phathom Pharmaceuticals, INC. | $35.02 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $34.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.42 | 2019-2020 | |
| Alk-Abello, INC | $30.01 | 2021-2022 | |
| Gilead Sciences, INC. | $21.41 | 2021 | |
| Phadia US INC. | $20.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2019 | |
| Baxter Healthcare | $17.54 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $11.89 | 2019 | |
| Therapeuticsmd, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.